Search company, investor...

Predict your next investment

Taiho Ventures company logo
Corporate Venture
taihoventures.com

Investments

31

Portfolio Exits

5

Funds

1

Partners & Customers

1

About Taiho Ventures

Taiho Ventures is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology. Taiho Ventures is a newly established strategic investor looking at early-stage preclinical oncology companies as well as platform technology companies for our core therapeutic areas. Taiho Ventures will review the wide variety of modalities for both biologics and small molecules mainly in US and European countries. The company will also consider the option-type of investments and spin-outs, in addition to the pure equity investments.

Headquarters Location

2420 Sand Hill Road Suite 203

Menlo Park, California, 94025,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Taiho Ventures News

13 European longevity startups hacking the ageing process

Feb 19, 2024

From cell reprogramming to gut health and health clinics — these are the longevity startups investors think you should keep an eye on 7 min read Longevity is sometimes seen as the search for a miracle drug that makes humans live forever, but for most people in the field, the focus is on making us as healthy in the last 20-30 years of our lives as we were in our 30s and 40s. In 2022, longevity-specific startups raised $5.2bn. But increasingly, healthtechs working on preventative health also fit the description — like Danish pharmaceutical Novo Nordisk’s “miracle weight-loss drug” Ozempic, which has been demonstrated to improve heart failure-related symptoms in humans and help repair the DNA caused by neurodegenerative diseases in tests on mice, according to longevity expert Phil Newman. “Currently, the media attention is on weight loss; however, when researchers publish data on its longevity effect, we will see the potential of longevity drugs hitting the mainstream,” Newman says. Advertisement Novo Nordisk is a $297bn company, so nowhere near being a startup, but which European startups are likely to be the big winners in this space? Sifted asked four longevity investors and experts to share the companies they’re keeping an eye on. The only catch: none of the companies could be in their portfolios already. Michael Greve, founder of Kizoo Technology Ventures Kizoo has invested in UK cell therapy startup LIfT BioSciences, Swiss longevity startup Cellvie and others. Greve is also the founder of the Forever Healthy Foundation. Michael Greve at Kizoo Technology Ventures Cellbricks — Germany Cellbricks, founded in 2015, has developed a 3D printer system for artificially made organs. It is working toward a future where bio-fabrication of organs and human tissue is a common medical practice — to give humans longer and healthier lives. Founder: Dr Lutz Kloke Epiterna — Switzerland Epiterna was founded in 2022 as a spinoff from the University of Lausanne. It has developed a platform to evaluate drugs and assess their effect on healthy lifespan. To ensure that its medicines could be used within years, not decades, the company is developing products using drugs and chemical compounds that have already been approved to treat humans, dogs and cats for specific diseases. Founders: Kevin Perez, Alejandro Ocampo Rejuvenate Biomed — Belgium Rejuvenate Biomed is a biomedical company developing novel combination drugs for age-related diseases. The company has developed a proprietary AI screening platform to evaluate if safe, existing treatments can be used in new combinations to maintain our natural cellular resilience and postpone the onset of certain age-related diseases. It is now working on the clinical development of its lead drug candidate in sarcopenia, an age-related disease defined by losing muscle strength, quality and mass. Founder: Dr Ann Beliën Marc P. Bernegger, cofounder of Maximon Maximon, a Swiss longevity company builder with a separate €96m fund for co-investments, has so far launched longevity supplement startup Avea, longevity data matrix Biolytica and healthspan centre Ayun , opening at the beginning of 2024. Marc P. Bernegger at Maximon GlycanAge — UK Founded in 2020, GlycanAge is focused on measuring people’s biological ageing by checking the blood for glycan, sugar molecules that surround and modify proteins in your body. With an at-home blood test, the company tests a sample to give users their biological age, as well as offering a video consultation to help users improve their health. Founders: Gordan Lauc, Nikolina Lauc Most recent funding: Undisclosed grant in 2022 Muhdo — UK Founded in 2016, Muhdo offers users at-home DNA tests to give them a better understanding of how lifestyle, nutrition and environment can affect how their genes function and express themselves. It also offers brain-training exercises and skin-aging face analysis. Founders: Dale Holdback, James Brown Most recent funding: Undisclosed Ani Biome — Croatia Founded in 2022, Ani Biome focuses on microbiome health. Its platform provides users with an analysis by using non-invasive diagnostics, including daily questions about mental, biological and sociological wellbeing, as well as tongue and skin scans, and data from wearables. With AI algorithms, it creates a personalised AgeBiotics monthly plan and metabolic microbeverages produced by fermentation. Advertisement Most recent funding: $1m seed round in 2023 Alexandra Bause, cofounder and partner of Apollo Health Ventures The transatlantic VC and company builder raised a $180m fund in 2021 and has invested in companies including Samsara Therapeutics and Cleara Biotech. Alexandra Bause at Apollo Health Ventures Cellvie — Switzerland Founded in 2020, Cellvie is developing technology that will allow therapeutic mitochondria transplantation. Mitochondria are the powerhouses of the cell, and mitochondrial dysfunction may be one of the essential drivers of age-related degeneration. Cellvie’s technology aims to reintroduce functional mitochondria into organs with failing mitochondria, which may increase the survival of tissues upon acute injury but may also help reinvigorate ageing tissues in general. Founders: Dr Alex Schueller, Dr Pedro del Nido, Dr James McCully, Dr Sitaram Emani Latest funding: $5.5M financing led by Taiho Ventures LLC in 2023 Senisca — UK Founded in 2020 as a biotech spinout company from the University of Exeter, Senisca is dedicated to the development of new approaches to prevent cellular senescence (a major hallmark of ageing) by targeting a process called alternative splicing. This approach may help restore the ability of cells to “fine tune” the expression of their genes to rejuvenate aged cells, which may be leveraged to target age-related diseases and aesthetic signs of ageing. Founders: Lorna Harries, Dr Ben Lee, Kirsty Semple Latest funding: £2m seed funding from Emerging Longevity Ventures (ELV), R42group, QANTX and APEX Ventures Telomere Therapeutics — Spain Founded in 2020 as a spinoff from the University of Barcelona, Telomere Therapeutics is developing a telomerase gene therapy that counteracts telomere shortening and can treat age-related diseases. One of the key reasons we age is the protective caps at the end of our chromosomes, called telomeres, shorten over time. When they fully disintegrate, it causes our DNA to become damaged. Founders: Maria Blasco and Fàtima Bosch Latest funding: €1.8m by Spanish Invivo Ventures in 2021 Phil Newman, founder of  First Longevity Apart from being the founder of the longevity investment brokerage business First Longevity, Newman is also editor-in-chief at the longevity media site Longevity.Technology. Phil Newman at First Longevity Clock.bio — UK Founded in 2020, Clock.bio focuses on rejuvenating cells with the newly developed human induced pluripotent stem cell (hiPSC) technology. By developing an ageing model that force-ages hiPSCs and triggers their self-rejuvenation mechanism, the company aims to leverage the natural ability of human pluripotent stem cells to prevent and treat age-related diseases. Founder: Mark Kotter Shift Bioscience — UK Founded in 2017, Shift Bioscience believes that reprogramming of the cells will lead to a rapid development of new treatments for a range of diseases associated with old age, such as neurodegenerative diseases, liver disease and sight loss. The aim is to identify safe rejuvenation factors that reset cells and tissues to a youthful state, with the help of deep learning models. Founders: Daniel Ives, Brendan Swain, Steve Ives Most recent funding: Undisclosed seed round by Kindred Capital and F-Prime in 2022 MitoRx Therapeutics — UK MitoRx Therapeutics, founded in 2021, is a pre-clinical biotech startup developing novel therapeutics, with a mission to develop medicines for degenerative diseases driven by mitochondrial dysfunction. It is now developing orally delivered mitochondrial protective therapeutics, targeting rare neuromuscular disorders, rare metabolic diseases and neurodegenerative diseases. Founders: Jon Rees, Norman Law Most recent funding: Undisclosed seed round in 2022 Neko Health — Sweden Founded in 2018, Neko Health is not commonly perceived as a longevity company but rather a preventative care clinic. Since earlier this year, it offers non-invasive examinations which collect over 50 million data points about the skin, heart, vessels, respiration, inflammation and more. Neko’s technology is based on AI, and therefore the company expects its diagnostic ability to improve over time. Founders: Daniel Ek, Hjalmar Nilsonne Most recent funding: €60m Series A by Atomico and General Catalyst in July 2023 Advertisement

Taiho Ventures Investments

31 Investments

Taiho Ventures has made 31 investments. Their latest investment was in EpiBiologics as part of their Series A - II on July 20, 2023.

CBI Logo

Taiho Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/20/2023

Series A - II

EpiBiologics

$23M

Yes

1

5/2/2023

Seed VC - II

Anavo Therapeutics

$9.32M

No

3

2/6/2023

Seed VC - II

cellvie

$5.5M

Yes

4

12/14/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/4/2022

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/20/2023

5/2/2023

2/6/2023

12/14/2022

11/4/2022

Round

Series A - II

Seed VC - II

Seed VC - II

Series B

Series A - II

Company

EpiBiologics

Anavo Therapeutics

cellvie

Subscribe to see more

Subscribe to see more

Amount

$23M

$9.32M

$5.5M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

3

4

10

10

Taiho Ventures Portfolio Exits

5 Portfolio Exits

Taiho Ventures has 5 portfolio exits. Their latest portfolio exit was Werewolf Therapeutics on April 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/30/2021

IPO

$99M

Public

5

4/24/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/9/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

2/8/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/15/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/30/2021

4/24/2020

5/9/2019

2/8/2019

3/15/2018

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

Taiho Ventures Fund History

1 Fund History

Taiho Ventures has 1 fund, including Taiho Ventures I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/17/2018

Taiho Ventures I

$300M

4

Closing Date

10/17/2018

Fund

Taiho Ventures I

Fund Type

Status

Amount

$300M

Sources

4

Taiho Ventures Partners & Customers

1 Partners and customers

Taiho Ventures has 1 strategic partners and customers. Taiho Ventures recently partnered with Arcus Biosciences on September 9, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

9/20/2017

Partner

United States

Arcus Biosciences Announces Option and License Agreement with Taiho Pharmaceutical Co. Ltd.

HAYWARD , Calif. -- -- Arcus Biosciences , a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies , announced today that it has entered into an option and license agreement with Taiho Pharmaceutical , for the potential development and commercialization of product candidates in Arcus Biosciences 's portfolio in Japan and certain other territories in Asia .

2

Date

9/20/2017

Type

Partner

Business Partner

Country

United States

News Snippet

Arcus Biosciences Announces Option and License Agreement with Taiho Pharmaceutical Co. Ltd.

HAYWARD , Calif. -- -- Arcus Biosciences , a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies , announced today that it has entered into an option and license agreement with Taiho Pharmaceutical , for the potential development and commercialization of product candidates in Arcus Biosciences 's portfolio in Japan and certain other territories in Asia .

Sources

2

Taiho Ventures Team

1 Team Member

Taiho Ventures has 1 team member, including current Founder, Chief Executive Officer, President, Sakae Asanuma.

Name

Work History

Title

Status

Sakae Asanuma

Astellas Venture Management, Yasuda Enterprise Development, and Meiji Yasuda Life Insurance Company

Founder, Chief Executive Officer, President

Current

Name

Sakae Asanuma

Work History

Astellas Venture Management, Yasuda Enterprise Development, and Meiji Yasuda Life Insurance Company

Title

Founder, Chief Executive Officer, President

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.